Jack Ball's departure as CEO of Seattle-based Amnis Corporation, revealed last week, was the result of a difference in opinion over the aggressiveness with which the company should market its flagship ImageStream 100 imaging cytometer, CBA News has learned.

"The company really decided to take a different path to commercialization that didn't require the skill sets that I brought in," Ball said. "We just sort of differed on what was the best way to move forward commercially. I would say that [Amnis] wants a more low-key approach to commercialization."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.